PT  - JOURNAL ARTICLE
AU  - Wood, Madeline E.
AU  - Xiong, Lisa Y.
AU  - Wong, Yuen Yan
AU  - Buckley, Rachel F.
AU  - Swardfager, Walter
AU  - Masellis, Mario
AU  - Lim, Andrew S. P.
AU  - Nichols, Emma
AU  - Joie, Renaud La
AU  - Casaletto, Kaitlin B.
AU  - Kumar, Raj G.
AU  - Dams-O’Connor, Kristen
AU  - Palta, Priya
AU  - George, Kristen M.
AU  - Satizabal, Claudia L.
AU  - Barnes, Lisa L.
AU  - Schneider, Julie A.
AU  - Binet, Alexa Pichette
AU  - Villeneuve, Sylvia
AU  - Pa, Judy
AU  - Brickman, Adam M.
AU  - Black, Sandra E.
AU  - Rabin, Jennifer S.
AU - the ADNI and Prevent-AD Research Groups
TI  - Sex differences in associations between <em>APOE ε2</em> and longitudinal cognitive decline
AID  - 10.1101/2022.11.28.22282828
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.28.22282828
4099  - http://medrxiv.org/content/early/2022/11/29/2022.11.28.22282828.short
4100  - http://medrxiv.org/content/early/2022/11/29/2022.11.28.22282828.full
AB  - INTRODUCTION We examined whether sex modifies the association between APOE ε2 and cognitive decline across two independent samples.METHODS We used observational data from non-Hispanic White (NHW) and non-Hispanic Black (NHB) cognitively unimpaired adults. Linear mixed models examined interactive associations of APOE genotype (ε2 or ε4 carrier vs. ε3/ε3) and sex on cognitive decline in NHW and NHB participants separately.RESULTS In both Sample 1 (N=9,766) and Sample 2 (N=915), sex modified the association between APOE ε2 and cognitive decline in NHW participants. Specifically, relative to APOE ε3/ε3, APOE ε2 protected against cognitive decline in men but not women. Among APOE ε2 carriers, men had slower decline than women. Among APOE ε3/ε3 carriers, cognitive trajectories did not differ between sexes. There were no sex-specific associations of APOE ε2 with cognitive decline in NHB participants (N=2,010).DISCUSSION In NHW adults, APOE ε2 may selectively protect men against cognitive decline.Competing Interest StatementJAS: Scientific Advisory Board/Consultant: AVID radiopharmaceuticals (subsidiary of Lilly), Alnylam Pharmaceuticals, Apellis Pharmaceuticals, Takeda Pharmaceuticals, National Hockey League ASPL: Sat on a paid advisory board for Eisai within the past 12 months.Funding StatementThis study did not receive funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Board of Sunnybrook Research Institute gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the present study (i.e., NACC, ROS/MAP/MARS, ADNI, and Prevent-AD cohorts) is available upon separate requests by investigators to the relevant institutions for each data source.